Find-Health-Articles.com - making medical research available to everyone
Research article summary (published 13 Jul 2009):

Homocysteine levels after acute levodopa intake in patients with Parkinson's disease.

Full Abstract

Levodopa (L-dopa) administered with a dopadecarboxylase inhibitor (DDI) increases homocysteine plasma levels. This may support the onset of atherosclerosis-related disorders and neuropsychiatric complications in patients with Parkinson's disease (PD). This homocysteine elevation is considered as long-term effect of chronic L-dopa/DDI treatment. Little is known about the acute effects of L-dopa/DDI intake on homocysteine generation. The objective of this trial was to investigate the relations between L-dopa and homocysteine after acute L-dopa/DDI administration in PD patients with different L-dopa metabolism. Thirty PD patients were divided into groups with superior (I) and less (II) L-dopa absorption after standardized intake of 125 mg L-dopa/benserazide with determination of L-dopa, 3-O-methyl-dopa (3-OMD) and homocysteine in plasma at baseline, 30, 60, and 90 minutes. There was a homocysteine increase in Group I (F = 5; P = 0.005) and a moderate decrease in Group II (F = 4.27; P = 0.01). A rise of 3-OMD (F = 10.51; P < 0.0001) appeared in Group I, but not in Group II (F = 0.91; P = 0.44), accordingly L-dopa accumulation was better in Group I than in Group II. Thus, in conclusion, L-dopa metabolism is an important component for homocysteine elevation after one time L-dopa/DDI administration in PD patients. 2009 Movement Disorder Society.

 

Author information

Author/s: Müller, Thomas (T); Kuhn, Wilfried (W);

Affiliation: Department of Neurology, St. Joseph Hospital Berlin-Weissensee, Germany. th.mueller(-atsign-)alexius.de

Journal and publication information

Publication Type: Clinical Trial; Journal Article

Journal: Movement disorders : official journal of the Movement Disorder Society (Mov Disord), published in United States. (Language: eng)

Reference: 2009-Jul; vol 24 (issue 9) : pp 1339-43

Dates: Created 2009/08/03; Completed 2009/10/21;

PMID: 19425084, status: MEDLINE (last retrieved date: 10/21/2009)

Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.

External Links for this article
(including full text providers, if available):

Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.

This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.

MeSH headings (categories)

This article was linked to the MeSH Headings (categories) shown below.

Note: Bold headings indicate primary MeSH headings or qualifiers.

Associated Chemicals: 3-O-methyl-DOPA (0) ; Antiparkinson Agents (0) ; Levodopa (0) ; Homocysteine (454-28-4) ; Dihydroxyphenylalanine (63-84-3)

Related articles

These are the most related articles currently in our database:

See 100+ related articles.

Related Article Map

5/30/1986
12/30/2006
Higher Relevance Score (100)
Lower Relevance Score (50)

Legend: - FREE Full text Article. - Abstract only. - Title only. More help.

See a larger map of 100+ related articles.

© Advanogy LLC 2003-2010 - All rights reserved. Terms of Use | Contact Us | Index